<DOC>
	<DOCNO>NCT01225302</DOCNO>
	<brief_summary>The primary objective study assess safety pharmacokinetics linifanib , identify tolerable dose linifanib ( ABT-869 ) combination carboplatin paclitaxel Japanese subject advance metastatic non-small cell lung cancer ( NSCLC ) . Secondary objective obtain preliminary efficacy anti-tumor activity subject first-line treatment .</brief_summary>
	<brief_title>A Study Linifanib ( ABT-869 ) Combination With Carboplatin/Paclitaxel Japanese Subjects With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria The subject must 20 old year age . The subject must cytologically histologically confirm nonsquamous NSCLC . Subjects may mix histology must predominantly nonsquamous eligible . The subject must advance metastatic ( Stage IV [ According American Joint Committee Cancer ( AJCC ) stag manual , 7th edition ] ) disease amenable surgical resection radiation curative intent . The subject must receive prior chemotherapy NSCLC . The subject measurable disease , define least 1 unidimensionally measurable lesion CT scan define Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 . The subject Easter Cooperative Oncology Group ( ECOG ) Performance Score 01 . The subject must adequate bone marrow , renal hepatic function . Exclusion Criteria The subject hypersensitivity paclitaxel drug formulate polyethoxylated castor oil ( Cremophor ) . The subject receive anticancer therapy treatment NSCLC include investigational agent , immunotherapy , traditional Chinese medicine/herbal remedy , hormonal , `` target '' agent ( i.e. , erlotinib , imatinib ) , biologic therapy cytotoxic chemotherapy ( i.e. , alkylating agent , microtubule inhibitor , antimetabolite ) . The subject history another active cancer within past 5 year except cervical cancer situ , situ carcinoma bladder , squamous cell basal cell carcinoma skin . The subject active ulcerative colitis , Crohn 's disease , celiac disease condition interfere absorption . The subject medical condition , opinion study investigator place unacceptably high risk toxicity . The subject pregnant breast feeding . The subject NSCLC predominant squamous cell histology .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>